Mirvie Granted Breakthrough Device Designation For Test To Identify Risk Of Preeclampsia
Executive Summary
Mirvie’s RNA platform can identify 75% of women who develop preeclampsia months before symptoms occur.
You may also be interested in...
Newer Therapy Areas Will Drive Women’s Health Funding In 2024
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.
‘High Unmet Need’ For Better Treatments Will Drive Women’s Health Funding In 2024
Women’s health start-ups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors, experts say. Meanwhile, machine learning and AI, as well as next gen-treatments such as psychedelic therapy, stand to drive advancements in the space.
Minute Insight: Thermo Fisher Scientific Wins FDA Clearance For Preeclampsia Blood Test
The FDA cleared Thermo Fisher’s in vitro diagnostic for preeclampsia, the leading cause of pregnancy morbidity and mortality, based on results from the PRAECIS study.